AzTrials
AzTrials

BronchiolitisSTENP-PERNCT07901400

Short-Term Enteral Nutrition for Infants With Bronchiolitis in Pediatric Emergency Departments

A study testing Usual inpatient bronchiolitis care and STENP-PER care pathway in people with Bronchiolitis and Clinical Phenotype, run by Hospices Civils de Lyon at 8 sites in France.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Bronchiolitis is a common viral infection of the small airways that affects infants, particularly during respiratory syncytial virus epidemics. Some infants mainly develop feeding difficulties, with a marked reduction in milk intake or refusal to feed, while showing no immediate signs of severe respiratory impairment. Read more about this study

Who is it for?
Ages 8 weeks to 12 months
What is being tested?
Usual inpatient bronchiolitis care and STENP-PER care pathway
Could I receive a placebo?
No, everyone receives an active treatment
How many people
448 participants
Where
8 sitesFrance
Study dates
1 Nov 2026to 1 Nov 2030
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 8 weeks to 12 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Infant presenting to the pediatric emergency department of a participating center between the beginning and end of the respiratory syncytial virus (RSV) epidemic, as determined by the hospital virology laboratory or regional indicators from Santé publique France.
  • Infant meeting the clinical criteria for bronchiolitis:
  • An acute episode of respiratory symptoms, including cough, wheezing and/or crackles, with or without rapid breathing (respiratory rate >50 breaths per minute for this age group, according to the World Health Organization) and/or signs of increased work of breathing (use of the lower intercostal or sternocleidomastoid accessory muscles, or thoracoabdominal asynchrony); and
  • An indication for nutritional support via a nasogastric tube and enteral feeding pump because of inadequate intake, defined as intake of less than 50% of the usual amount over the preceding 12 hours or refusal to feed.
  • At least 72 hours since the onset of respiratory symptoms, including rhinorrhea, nasal obstruction, signs of increased work of breathing, rapid breathing, or wheezing reported by the parents.
  • Corrected age of at least 8 completed weeks and chronological age of no more than 11 months and 30 days.
  • Covered by a French social security system.

Who cannot join

  • Neurological impairment: unresponsiveness and/or episodes of bradycardia with apnea.
  • Respiratory failure: oxygen saturation <90% during sleep or <92% while awake; pauses in breathing lasting ≥10 seconds; respiratory rate >70 or <30 breaths per minute; or severe, persistent signs of increased work of breathing.
  • One or more vulnerability criteria or risk factors for severe disease: a comorbidity (congenital heart disease with a shunt, chronic lung disease including bronchopulmonary dysplasia, neuromuscular disease, immunodeficiency, or severe multiple disabilities) or a heart rate >180 or <80 beats per minute.
  • Weight-for-age z-score at emergency department admission, adjusted for gestational age using INSERM growth charts: <0 standard deviations for infants born before 37 weeks of gestation, or <-2 standard deviations for infants born at term.
  • A condition increasing the risk of failed nasogastric tube placement or related complications, such as an upper airway malformation or a systemic or local bleeding disorder.
  • Recurrence of bronchiolitis without a return to normal respiratory status in the preceding four weeks.
  • An unfavorable home situation: parents unable to understand the protocol or questionnaires, discharge home on Day 0 not possible, or no telephone available for follow-up.
  • Parents declining participation.

Trial locations and contacts

8 sites in 1 country. Contact the study team or a site near you to ask about taking part.

8 sites in 1 country

France8 sites
  • CHU Clermont-Ferrand, Hôpital Estaing

    Clermont-Ferrand, 63100

    Tara INGRAO, Dr, 04 73 75 52 90 ext. +33, tingrao@chu-clermontferrand.fr

    Emanuelle Rochette, 04 73 75 22 97 ext. +33, e_rochette@chu-clermontferrand.fr

  • AP-HP, Hôpital Louis-Mourier

    Colombes, 92700

    Romain BASMACI, MD PhD, 01 47 60 63 58 ext. +33, romain.basmaci@aphp.fr

    Odile LAURENT, 01 47 60 63 58 ext. +33, odile.laurent@aphp.fr

  • Hôpital Nord-Ouest Villefranche

    Gleizé, 69655

    Gaelle RAISIN, MD, 04 74 09 67 72 ext. +33, graisin@hno.fr

    Coline PERRIER, 04 74 09 24 73 ext. +33, cperrier@hno.fr

  • AP-HM, Hôpital Nord

    Marseille, 13015

    Sandrine HAUPT, MD, 04 91 96 88 13 ext. +33, sandrine.haupt@ap-hm.fr

    Renaud Viallet, MD, Clinical research, 04 91 96 46 14 ext. +33, renaud.vialet@ap-hm.fr

  • CHU de Montpellier, Hôpital Arnaud de Villeneuve

    Montpellier, 34295

    Eric Jeziorski, MD, PhD, 04 67 33 22 86 ext. +33, e-jeziorski@chu-montpellier.fr

    Carine JAILLET, 04 67 33 66 43 ext. +33, c-jaillet@chu-montpellier.fr

  • CHU de Nantes

    Nantes, 4400

    Bénédicte Vrignaud, MD, 02 40 08 79 36 ext. +33, benedicte.vrignaud@chu-nantes.fr

    Anne DROUARD, 0240 0878 05 ext. +33, Anne.DROUARD@chu-nantes.fr

  • Hôpitaux Pédiatriques de Nice CHU-Lenval

    Nice, 06200

    Antoine TRAN, MD, PhD, 04 92 03 04 42 ext. +33, antoine.tran@hpu.lenval.com

    Ghaleb Zouzou, 0492030585 ext. +33, ghaleb.zouzou@hpu.lenval.com

  • CHU de Saint-Étienne, Hôpital Nord

    Saint-Etienne, 42055

    Aymeric CANTAIS, MD, 04 77 82 81 34 ext. +33, aymeric.cantais@chu-st-etienne.fr

    Eva GLAIZES, 04 77 82 94 10 ext. +33, eva.gleizes@chu-st-etienne.fr

Other trials in France

About this study

Official title: Evaluation of Short-Term Enteral Nutrition in Pediatric Emergency Departments for Young Infants With Bronchiolitis and Predominant Nutritional Impairment

Bronchiolitis is a common viral infection of the small airways that affects infants, particularly during respiratory syncytial virus epidemics. Some infants mainly develop feeding difficulties, with a marked reduction in milk intake or refusal to feed, while showing no immediate signs of severe respiratory impairment. These infants often need nutritional support through a nasogastric tube, which is a small tube passed through the nose into the stomach. Under usual care, starting enteral nutrition generally requires admission to a pediatric short-stay unit or a conventional inpatient ward.

The purpose of this study is to determine whether a short period of enteral nutrition provided directly in the pediatric emergency department can reduce the total number of days spent in hospital during the 14 days following inclusion, compared with usual inpatient care. The short-term pathway is called the Short-Term Enteral Nutrition Protocol in the Pediatric Emergency Room (STENP-PER).

Read more

The study will include 448 infants treated in eight pediatric emergency departments in France. Eligible infants will be between 8 completed weeks of corrected age and 11 months and 30 days of chronological age. They must have bronchiolitis, have had respiratory symptoms for at least 72 hours, and require nutritional support because their feeding has fallen below half of the usual amount during the previous 12 hours or because they refuse to feed. Infants with signs of severe respiratory, neurological, or nutritional illness, important medical risk factors, or circumstances that would make discharge or follow-up unsafe will not be included.

This is a cluster-randomized stepped-wedge study. This means that the pediatric emergency departments, rather than individual infants, will be randomly assigned to the order in which they introduce the STENP-PER pathway. All participating departments will initially provide usual inpatient care. They will then progressively switch to the new pathway over four annual respiratory syncytial virus epidemic seasons. Each department will therefore contribute information during both a usual-care period and an intervention period.

During the usual-care period, infants will be admitted to a pediatric short-stay unit or conventional inpatient ward for enteral nutrition and clinical monitoring, according to the usual procedures of each hospital.

During the STENP-PER period, trained emergency department staff will place a nasogastric tube and provide continuous enteral nutrition for six hours while monitoring the infant's general condition, breathing, vital signs, and any adverse events. A parent will remain with the infant whenever possible. Parents will receive practical education, including information and instruction on nasal clearance. After six hours, the infant will be reassessed by the clinical team. If the infant's condition allows it, the infant will return home. If hospital monitoring or treatment is still needed, the infant will be admitted according to usual care. Participation in the study will not prevent clinicians from changing or stopping the feeding procedure when this is considered necessary for the infant's safety.

The infant's health and use of healthcare services will be followed from inclusion through Day 14. Information will be obtained from hospital records and through a telephone call with the parents around Day 14. The main outcome is the total number of days spent in hospital during this period. This includes an immediate hospital stay after the first emergency department visit and any later hospitalization or rehospitalization related to the same episode of bronchiolitis or its management.

The study will also compare the percentage of infants admitted immediately, the percentage transferred to another hospital, parents' satisfaction and experience of care, parents' understanding of advice about bronchiolitis, healthcare professionals' satisfaction, and the number and type of adverse events. The investigators will also examine how well the pathway is introduced and followed in each emergency department, how acceptable it is to families and healthcare professionals, the barriers and factors supporting its use, and whether it can be maintained and transferred to other hospitals. Interviews with parents and group discussions with healthcare professionals will provide additional information about their experience. Finally, a health-economic evaluation will compare the costs of the two care strategies over 14 days.

The study is expected to show whether providing short-term enteral nutrition in the pediatric emergency department is a safe and effective alternative to systematic hospital admission for carefully selected infants with bronchiolitis and predominant feeding difficulties.

Read the detailed description

Bronchiolitis is one of the most common causes of hospital admission in infants during the winter season. Although respiratory symptoms are usually the main concern, some infants present with a predominantly nutritional phenotype characterized by a marked reduction in feeding or feeding refusal. These infants may require enteral nutritional support even when they do not have severe respiratory failure or other established risk factors for severe bronchiolitis.

Under current practice, the need for enteral nutrition generally results in hospital admission, either to a pediatric short-stay unit or to a conventional inpatient ward. However, hospital capacity is frequently under considerable pressure during respiratory syncytial virus epidemics. Systematic admission of infants who mainly require temporary nutritional support may contribute to bed shortages, inter-hospital transfers, prolonged waiting times, and organizational difficulties for families and healthcare teams.

The Short-Term Enteral Nutrition Protocol in the Pediatric Emergency Room (STENP-PER) was developed as an alternative care pathway for carefully selected infants with bronchiolitis and predominant nutritional insufficiency. The programme aims to provide early nutritional treatment and clinical monitoring directly in the pediatric emergency department, while avoiding conventional hospital admission when the infant's condition permits safe discharge home.

A preliminary feasibility and proof-of-concept study conducted in Lyon suggested that a six-hour enteral nutrition pathway in the pediatric emergency department was feasible and was positively perceived by families and healthcare professionals. The preliminary findings also suggested that most clinical deteriorations requiring hospital admission occurred during the initial monitoring period and that hospital admissions following discharge mainly occurred during the first few days. These findings supported the selection of a 14-day follow-up period for the present study.

STENP-PER is a multifaceted intervention that combines a standardized clinical care pathway with measures intended to support its implementation. Its main components include education and training of medical and paramedical staff, standardized tools to support delivery of the pathway, and implementation facilitation adapted to the organization and resources of each participating department.

During the intervention period, the infant is cared for in a bed in the pediatric emergency department, with a parent present whenever possible. A trained pediatric nurse inserts a nasogastric tube and initiates six hours of continuous enteral nutrition using an enteral feeding pump. The infant's general condition, respiratory status, vital signs, feeding tolerance, and any adverse events are monitored throughout the procedure.

Parents receive therapeutic education, including information about the benefits and potential risks of nasal clearance, a practical demonstration, and supervised practice when appropriate. Participating departments may provide additional education according to their usual practices and priorities, e.g. advice on safe sleeping and the prevention of exposure to tobacco smoke.

At the end of the six-hour period, the infant is clinically reassessed. Infants whose condition is compatible with discharge return home with instructions concerning monitoring, reasons for seeking further medical care, and contact details for the pediatric emergency department. If the infant develops signs requiring hospital monitoring or treatment, the care pathway is converted to conventional hospital admission. Clinical decisions remain under the responsibility of the treating team, and the procedure may be modified, slowed, interrupted, or stopped whenever necessary for the infant's safety.

The comparator is the current usual-care strategy. During control periods, infants who require nasogastric enteral nutritional support are admitted to a pediatric short-stay unit or conventional inpatient ward. Enteral nutrition and clinical monitoring are then provided in accordance with the usual procedures of each participating hospital.

The effectiveness of the STENP-PER programme will be evaluated using a multicentre, cluster-randomized stepped-wedge superiority design. The unit of randomization is the pediatric emergency department rather than the individual infant because the intervention involves changes in professional practice, staff training, task organization, and the local care pathway. Individual randomization within the same department would create a substantial risk of contamination between the two strategies.

Eight pediatric emergency departments in France will participate. The study will be conducted over four consecutive annual respiratory syncytial virus epidemic seasons. During the first period, all participating departments will provide usual care. The departments will then switch progressively to the STENP-PER programme according to a randomized implementation sequence. Three departments will switch to the intervention during the second period, three during the third period, and the remaining two during the fourth period. Once a department has implemented STENP-PER, it will continue to use the programme during subsequent study periods.

The order of implementation will be generated by the Biostatistics Department of Hospices Civils de Lyon. Training and local preparation will take place between epidemic seasons before each department begins its intervention period. Because every department contributes observations during both control and intervention periods, each department acts as its own control. This design helps account for differences between hospitals in activity levels, available resources, patient populations, organizational characteristics, and usual practices.

Recruitment will be restricted to the respiratory syncytial virus epidemic period at each participating centre. The beginning and end of each recruitment period will be determined using information from the hospital virology laboratory or regional indicators provided by Santé publique France. Fourteen infants will be enrolled per centre during each epidemic season, resulting in a total anticipated sample of 448 participants.

Each participant will be followed from inclusion through Day 14. Clinical and healthcare-use information will be collected from the medical record, hospital data systems, and a telephone interview with the parents around Day 14. The telephone follow-up will be used to document the infant's clinical course, any subsequent medical consultations, hospitalizations or rehospitalizations, the parents' experience of care, and their understanding of the information provided during the initial visit.

The primary analysis will compare the cumulative number of hospitalization days through Day 14 between the STENP-PER and usual-care strategies. All hospital stays associated with the initial episode will be considered, including immediate admission following the index emergency department visit and any subsequent hospitalization or rehospitalization related to worsening bronchiolitis or a complication of its management.

Additional analyses will evaluate the effects of the programme on immediate hospital admission, inter-hospital transfer, parent satisfaction and experience, parental knowledge, healthcare professional satisfaction, safety, and tolerance. Adverse events of particular interest include persistent nutritional insufficiency, the development of respiratory failure, nasogastric tube displacement or removal, and aspiration. Safety events will be reviewed and classified using standardized procedures established by the study's Event Validation Committee.

The study also includes an implementation evaluation guided by the integrated Promoting Action on Research Implementation in Health Services framework. External facilitators from the Lyon expert centre will work with local medical and paramedical facilitators in each participating department. This process will support the adaptation of the programme to the local context while preserving its essential clinical components.

Implementation will be evaluated in terms of fidelity, acceptability, sustainability, and transferability. Service-level fidelity will describe whether the programme components were implemented as planned. Participant-level fidelity will assess compliance with the intended duration and flow rate of enteral nutrition, completion of parent education, and reasons for deviations from the pathway. The proportion of eligible infants who receive STENP-PER during intervention periods will also be examined.

Acceptability, barriers, and facilitating factors will be explored from the perspectives of healthcare professionals and parents. Focus groups or individual interviews will be conducted with healthcare professionals and local facilitators in each participating department. Semi-structured interviews will also be proposed to approximately 14 to 20 parents who experienced the intervention. These interviews will explore their experience of the care pathway, their perception of safety, their acceptance of early discharge, and the organizational or personal factors that may influence implementation.

The transferability evaluation will examine whether the programme developed at the Lyon expert centre can be adapted and implemented in pediatric emergency departments with different organizational contexts. Information from implementation follow-up, professional focus groups, parent interviews, participant characteristics, fidelity indicators, and programme maintenance will be combined to identify the conditions required for wider deployment.

A health-economic evaluation will compare the costs of STENP-PER with those of usual inpatient care from the perspective of the healthcare system over the 14-day follow-up period. The cost of the intervention pathway will be estimated using a micro-costing approach that includes staff time and the consumables required for the procedure. Other healthcare costs will include emergency department care, initial hospitalization, transfers, and rehospitalizations. This evaluation will determine whether the new pathway can reduce resource use and costs while maintaining safe and appropriate care.

The study uses a hybrid effectiveness-implementation design because the clinical effect of STENP-PER may depend on how successfully the programme is introduced into routine practice. The effectiveness, safety, implementation, and economic findings will therefore be interpreted together. This combined approach is intended to determine not only whether STENP-PER reduces hospital use, but also under which organizational conditions it can be safely maintained and transferred to other pediatric emergency departments.

Being tested
Usual inpatient bronchiolitis care, STENP-PER care pathway
Keywords
Infant, bronchiolitis, enteral nutrition, nasogastric tube, pediatric emergency department, stepped-wedge cluster randomized trial, implementation science, health economics, respiratory syncytial virus, Short-Term Enteral Nutrition, clinical phenotype, nutritionnal impairment
Medical subject headings
Bronchiolitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Usual inpatient bronchiolitis careOther

    Hospital admission for enteral nutrition and monitoring in a pediatric short-stay or conventional inpatient unit, in accordance with the usual practice of each centre

  • STENP-PER care pathwayOther

    The STENP-PER program combines staff training, standardized care tools, and implementation support. In the pediatric emergency department, any recruited patient has a nasogastric tube insertion by a trained pediatric nurse to allow a continuous enteral nutrition administration for six hours. The clinical team monitors the infant's condition, vital signs, feeding tolerance, and adverse events. Parents receive education on nasal clearance. After six hours, the infant is reassessed and discharged home if clinically appropriate; otherwise, the infant is admitted for usual inpatient care.

Study groups in NCT07901400
Study groupRoleWhat they receive
Usual Inpatient CareActive comparatorDuring the control period, eligible infants receive usual care consisting of systematic hospital admission to a pediatric short-stay or conventional inpatient unit for enteral nutritional support and clinical monitoring according to local practice.
Receives: Other: Usual inpatient bronchiolitis care
STENP-PER care pathwayExperimentalDuring the intervention period, trained emergency department teams provide six hours of enteral nutrition and clinical monitoring in the pediatric emergency department. Parents receive education on nasal clearance. The infant is reassessed after six hours and discharged home when clinically appropriate; otherwise, the infant is admitted for usual inpatient care.
Receives: Other: STENP-PER care pathway

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean total number of hospitalization days through day 14

    For each infant, the cumulative number of days spent in conventional hospitalization will include hospitalization immediately following the index pediatric emergency department visit and any subsequent hospitalization or rehospitalization through Day 14 for worsening bronchiolitis or a complication related to management of the index episode. Hospital records and discharge reports will be checked against information obtained during the Day 14 parent telephone call. The mean number of days will be estimated for each study group and compared using a mixed-effects regression model accounting for clustering by center.

    Measured: Up to day 14

Secondary outcomes (10)
  1. Percentage of infants conventionally hospitalized immediately after the emergency department visit

    Percentage of enrolled infants admitted to conventional inpatient care immediately after the pediatric emergency department visit that led to inclusion. The percentage will be compared between study groups using a mixed-effects logistic regression model.

    Measured: Day 0

  2. Percentage of infants transferred to another hospital for immediate hospitalization

    Percentage of enrolled infants transferred to another hospital for immediate hospitalization following the index pediatric emergency department visit. The percentage will be compared between study groups using a mixed-effects logistic regression model.

    Measured: Day 0

  3. Parent Satisfaction Index Score Day0

    Parent satisfaction with the infant's care will be assessed using the study-specific standardized questionnaire. It covers information about bronchiolitis and its management, involvement in care, comfort and perceived safety during care, and perceived quality of care. Scores will be summarized by study group.

    Measured: Day 0

  4. Parent Satisfaction Index Score Day14

    Parent satisfaction with the infant's care will be assessed using the study-specific standardized questionnaire. It covers information about bronchiolitis and its management, involvement in care, comfort and perceived safety during care, and perceived quality of care.

    Measured: Day 14

  5. Parent Experience PPE-15

    Parent experience assessed by telephone with the 15-item Picker Patient Experience Questionnaire (PPE-15) adapted for pedriatric care.

    Measured: Day14

  6. Percentage of parents able to recall advice at Day 14

    Percentage of parents who recall the advice provided, assessed by telephone using the study-specific questionnaire. The percentage will be compared between study groups using a mixed-effects logistic regression model.

    Measured: Day 14

  7. Healthcare professional satisfaction score

    Medical and paramedical staff ratings of perceived quality of service to families, department crowding, and team cohesion. Each item is rated on a four-point Likert scale; individual items and their mean will be reported.

    Measured: 2 years, 3 years and 4 years (at the end of each center's first bronchiolitis epidemic season following implementation of the intervention)

  8. Percentage of infants with at least one adverse event

    Percentage of infants experiencing at least one adverse event during the 14 days following inclusion. Events will also be described by nature, severity, and cause category, including disease progression and care organization, after event validation committee review.

    Measured: Up to Day 14

  9. Percentage of infants with at least one adverse serious adverse event

    Percentage of infants experiencing at least one serious adverse event during the 14 days following inclusion. Events will also be described by nature, severity, and cause category, including disease progression and care organization, after event validation committee review.

    Measured: Up to Day 14

  10. Mean cost of infant care

    Mean healthcare cost per participant from the healthcare-system perspective, including emergency care, hospitalization, rehospitalization, personnel, and consumables. The intervention pathway will be evaluated using mixed bottom-up and top-down micro-costing methods.

    Measured: Up to Day 14

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Oct 2026
  2. Study start1 Nov 2026 (estimated)
  3. Primary completion1 Nov 2030 (estimated)
  4. Study completion1 Nov 2030 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Sequential
Model description
Multicentre superiority trial with cluster randomization and a stepped-wedge design. Eight pediatric emergency departments are assigned to one of three intervention rollout sequences across four epidemic seasons. All clusters start with usual care and subsequently cross to the STENP-PER pathway; no cluster returns to control.
Masking
None (open label)
Enrolment
448 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07901400
Sponsor's protocol ID
69HCL25_0925
Other IDs
2026-A01477-44
Acronym
STENP-PER
Status last verified
Oct 2026
First submitted
15 Oct 2026
Last updated
28 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Usual inpatient bronchiolitis care and STENP-PER care pathway in people with Bronchiolitis and Clinical Phenotype, run by Hospices Civils de Lyon at 8 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 8 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Anne TERMOZ (04 27 85 63 00 ext. +33, anne.termoz@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean total number of hospitalization days through day 14 (time frame: Up to day 14). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in